Santhera Debt To Equity from 2010 to 2026

SANN Stock  CHF 16.46  0.46  2.88%   
Santhera Pharmaceuticals Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2026. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
1.34
Current Value
1.94
Quarterly Volatility
8.36638007
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Santhera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Santhera Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 24.4 M or Selling General Administrative of 12.1 M, as well as many indicators such as Price To Sales Ratio of 4.39, Dividend Yield of 0.0 or PTB Ratio of 3.78. Santhera financial statements analysis is a perfect complement when working with Santhera Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Santhera Pharmaceuticals Technical models . Check out the analysis of Santhera Pharmaceuticals Correlation against competitors.
The evolution of Debt To Equity for Santhera Pharmaceuticals Holding provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Santhera Pharmaceuticals compares to historical norms and industry peers.

Latest Santhera Pharmaceuticals' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Santhera Pharmaceuticals Holding over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Santhera Pharmaceuticals' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Santhera Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 196.00 %10 Years Trend
Pretty Stable
   Debt To Equity   
       Timeline  

Santhera Debt To Equity Regression Statistics

Arithmetic Mean2.28
Geometric Mean1.08
Coefficient Of Variation366.43
Mean Deviation3.63
Median1.65
Standard Deviation8.37
Sample Variance70.00
Range43.5616
R-Value0.12
Mean Square Error73.53
R-Squared0.02
Significance0.64
Slope0.20
Total Sum of Squares1,120

Santhera Debt To Equity History

2026 1.94
2025 1.34
2024 1.49
2023 0.38
2022 -1.02
2021 32.36
2020 -11.2

About Santhera Pharmaceuticals Financial Statements

Santhera Pharmaceuticals investors use historical fundamental indicators, such as Santhera Pharmaceuticals' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Santhera Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 1.34  1.94 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Santhera Stock Analysis

When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.